Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2020 Filed Sep 4, 2020 19:50 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President and CEO · 10% owner
|
GrantRestricted Stock Units · Derivative | 7,220 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000020 · edgar.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,220 Underlying: Bio-Rad A Common Stock · 7,220 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:46 UTC |
Daskal IlanEVP, Chief Financial Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,166 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001812865-20-000016 · edgar.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Underlying: Bio-Rad A Common Stock · 2,166 shares Expires 2030-09-02 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:46 UTC |
Daskal IlanEVP, Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 2,166 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000016 · edgar.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166 Underlying: Bio-Rad A Common Stock · 2,166 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:44 UTC |
TUMOLO ANNETTEExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,733 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001812865-20-000014 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires 2030-09-02 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:44 UTC |
TUMOLO ANNETTEExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 1,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000014 · edgar.xml · derivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:35 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,610 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001812865-20-000012 · edgar.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,610 Underlying: Bio-Rad A Common Stock · 3,610 shares Expires 2030-09-02 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:35 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
GrantRestricted Stock Units · Derivative | 3,610 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000012 · edgar.xml · derivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,610 Underlying: Bio-Rad A Common Stock · 3,610 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:07 UTC |
WRIGHT DARAExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,733 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001812865-20-000010 · edgar.xml · derivative · entry 2 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires 2030-09-02 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:07 UTC |
WRIGHT DARAExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 1,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000010 · edgar.xml · derivative · entry 1 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:03 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
GrantRestricted Stock Units · Derivative | 963 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000008 · edgar.xml · derivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 Underlying: Bio-Rad A Common Stock · 963 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 23 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 500 shares Expires 2028-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 4, 2019. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 22 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 5, 2018. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $160.37 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 21 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 8, 2017. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 20 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 11, 2016. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $119.54 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 19 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 10, 2015. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,200 | $0.00 Strike: $117.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 18 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,200 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 11, 2014. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 17 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,250 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 12, 2013. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $98.04 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 16 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2021-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in five equal annual installments beginning on November 4, 2012. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $84.57 | $0.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · derivative · entry 15 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2020-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 8, 2011. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 339 | $521.86 | $176,910.54 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 14 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,738 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.73 to $522.05, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 5,668 | $520.94 | $2,952,687.92 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 13 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,077 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.51 to $521.51, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 1,133 | $519.89 | $589,035.37 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 12 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,745 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.39 to $520.37, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 5,392 | $518.76 | $2,797,153.92 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 11 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,878 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.38 to $519.25, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 315 | $517.64 | $163,056.60 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 10 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,270 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.34 to $518.33, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 500 | $326.15 | $163,075.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 9 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $215.98 | $215,980.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 8 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,200 | $160.37 | $192,444.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 7 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 2,000 | $139.56 | $279,120.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 6 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,000 | $119.54 | $358,620.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 5 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,200 | $117.00 | $374,400.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,250 | $107.32 | $348,790.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $98.04 | $343,140.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 18:01 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $84.57 | $295,995.00 |
DisclosureSEC source: 0001315406-20-000014 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 16:42 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 2,382 | $518.81 | $1,235,805.42 |
DisclosureSEC source: 0001315406-20-000012 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,435 Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 23:02 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $84.57 | $0.00 |
DisclosureSEC source: 0001315406-20-000010 · edgar.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 37,000 shares Expires 2020-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on September 8, 2011. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 23:02 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 21,860 | $448.85 | $9,811,861.00 |
DisclosureSEC source: 0001315406-20-000010 · edgar.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,122 Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 23:02 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 37,000 | $84.57 | $3,129,090.00 |
DisclosureSEC source: 0001315406-20-000010 · edgar.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:11 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 1,500 | $485.40 | $728,100.00 |
DisclosureSEC source: 0001812865-20-000002 · edgar.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310 Read SEC document |
| May 13, 2020 Filed May 14, 2020 17:11 UTC |
HUTTON RONALD WVice President and Treasurer
|
SaleBio-Rad A Common Stock | 443 | $457.35 | $202,606.05 |
DisclosureSEC source: 0001315406-20-000008 · edgar.xml · nonDerivative · entry 1 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,140.3386 F1 · balance_after: Includes 6.0157, 4.9675 and 5.4106 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 9/30/2019, 12/31/2019 and 3/31/2020, respectively. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 18:14 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-20-000002 · edgar.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning on April 29, 2020. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning on April 29, 2020. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 18:14 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 346 | $436.27 | $150,949.42 |
DisclosureSEC source: 0001652252-20-000002 · edgar.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679.9765 Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 18:14 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-20-000002 · edgar.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025.9765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 25.9765 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 3/31/2020. Read SEC document |
| April 29, 2020 Filed May 1, 2020 15:27 UTC |
RAMALINGAM AJITEVP, Chief Accounting Officer
|
GrantRestricted Stock Units · Derivative | 1,384 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000006 · edgar.xml · derivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · EVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384 Underlying: Bio-Rad A Common Stock · 1,384 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 17:07 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000004 · edgar.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning on April 8, 2020. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning on April 8, 2020. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 17:07 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 243 | $403.06 | $97,943.58 |
DisclosureSEC source: 0001315406-20-000004 · edgar.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457 Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 17:07 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000004 · edgar.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 23:30 UTC |
WRIGHT DARAExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,511 | $0.00 Strike: $366.89 | $0.00 |
DisclosureSEC source: 0001315406-19-000022 · edgar.xml · derivative · entry 2 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511 Underlying: Bio-Rad A Common Stock · 2,511 shares Expires 2029-12-16 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 23:30 UTC |
WRIGHT DARAExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 2,511 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-19-000022 · edgar.xml · derivative · entry 1 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,511 Underlying: Bio-Rad A Common Stock · 2,511 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 00:03 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-19-000077 · edgar.xml · derivative · entry 4 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Bio-Rad A Common Stock · 1,250 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning September 7, 2017 Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 00:03 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 656 | $370.12 | $242,798.72 |
DisclosureSEC source: 0001652252-19-000077 · edgar.xml · nonDerivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455.7039 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $370.01 to $370.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.